Add To Watchlist
Share URL
About The Company
Description
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India.
Read More
Overview
Value
14
Growth
85
Health
36
Management
71
Analyst Opinion
80
Total
57
All Scores Out Of 100
Best Features
- Very strong cashflow and earnings growth
- Earnings growth has improved recently
- Has a low level of debt
- Low risk of bankruptcy
- Liked by analysts
- Has strong dividend growth
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Income is not covering expenditure and investment
- There is a history of diluting shareholders
- No margin of safety at their current market price
- Price-to-earnings ratio of 27.9 is higher than the market average (19.6x)
- Cashflow is growing faster than revenue
Market Peers
KILITCH.NS
Key Figures
PE Ratio (TTM)
27.86
Margin Of Safety (DCF)
-61.77%
Revenue Growth (5 Year Average)
24.49%
Ratings Consensus
Buy
Share Buybacks
-4.15%
Dividend Yeild (TTM)
0.75%
Valuation
Value Score
14
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 108.8 INR ✘
Current Price: 152.6 INR
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
27.86x
Free Cashflow Yeild
-2.84%
PE/Earnings Growth
0.28
Price/Book
1.64x
Growth
Growth Score
85
- ✔ 5 Year Average Revenue growth of 24.49% is higher than the market average (10.97%)
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Earnings growth of 24.64% is higher than the market average (14.48%)
- ✔ Earnings growth has improved this year
- ✔ 5 Year Average Cashflow growth of 24.50% is higher than the market average (12.35%)
- ✔ Free Cashflow growth has improved this year
Revenue Growth
24.49%
Earnings Growth
24.64%
Cashflow Growth
24.50%
Health
Health Score
36
Altman Z Score
3.33
Piostroski Score
5.00
Debt/Equity
0.15x
Current Assets/Liabilities
1.65x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
0.18x
Management
Management Score
71
- ✔ Has issued new shares to finance growth when share price is high
- ✔ Has returned higher dividends when earnings have risen
- ✘ Return-on-capital-employed of 6.05% is lower than the market average (10%)
- ✘ Has a history of diluting shareholders to finance activity
- ✘ Return-on-equity of 5.25% is lower than the market average (15%)
Average Buybacks/Dilution
-4.15%
Recent Buybacks/Dilution
0.04%
5 Year Price Volitility
31.12%
Return On Assets
3.51%
Return On Capital Employed
6.05%
Return On Equity
5.25%
Return On Free Cashflow
78.74%
Return On Investments
28.27%
Analysts
Analyst Opinion
80
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Kilitch Drugs (India) Limited
Currency
INR
Beta
0.340515
Vol Avg
7543
Ceo
Cik
Cusip
Y4776K110
Exchange
National Stock Exchange of India
Full Time Employees
146
Industry
Drug Manufacturers—Specialty & Generic
Sector
Healthcare
Ipo Date
1994-02-14
Address
Village: Savroli, Taluka: Khalapur, Dist: Raigad
City
Mumbai
State
MAHARASHTRA
Country
IN
Zip
400088
Phone
912261214100
All financial data provided by FMP